| 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study P O'Connor, M Filippi, B Arnason, G Comi, S Cook, D Goodin, HP Hartung, ... The Lancet Neurology 8 (10), 889-897, 2009 | 515 | 2009 |
| Placebo-controlled trial of oral laquinimod for multiple sclerosis G Comi, D Jeffery, L Kappos, X Montalban, A Boyko, MA Rocca, M Filippi New England Journal of Medicine 366 (11), 1000-1009, 2012 | 442 | 2012 |
| Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial R Gold, G Giovannoni, K Selmaj, E Havrdova, X Montalban, EW Radue, ... The Lancet 381 (9884), 2167-2175, 2013 | 335 | 2013 |
| Three times weekly glatiramer acetate in relapsing–remitting multiple sclerosis O Khan, P Rieckmann, A Boyko, K Selmaj, R Zivadinov, ... Annals of neurology 73 (6), 705-713, 2013 | 300 | 2013 |
| Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings AJ Coles, JA Cohen, EJ Fox, G Giovannoni, HP Hartung, E Havrdova, ... Neurology 89 (11), 1117-1126, 2017 | 275 | 2017 |
| Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy E Havrdova, DL Arnold, JA Cohen, HP Hartung, EJ Fox, G Giovannoni, ... Neurology 89 (11), 1107-1116, 2017 | 229 | 2017 |
| Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? F Barkhof, HE Hulst, J Drulovic, BMJ Uitdehaag, K Matsuda, R Landin Neurology 74 (13), 1033-1040, 2010 | 163 | 2010 |
| Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage M Filippi, MA Rocca, E Pagani, N De Stefano, D Jeffery, L Kappos, ... Journal of Neurology, Neurosurgery & Psychiatry 85 (8), 851-858, 2014 | 139 | 2014 |
| Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial G Giovannoni, R Gold, K Selmaj, E Havrdova, X Montalban, EW Radue, ... The Lancet Neurology 13 (5), 472-481, 2014 | 105 | 2014 |
| Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study DH Miller, RJ Fox, JT Phillips, M Hutchinson, E Havrdova, M Kita, ... Neurology 84 (11), 1145-1152, 2015 | 81 | 2015 |
| Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials C Sampaio, J Bronzova, RA Hauser, AE Lang, O Rascol, SV van de Witte, ... Movement disorders 26 (8), 1464-1476, 2011 | 53 | 2011 |
| The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase III, placebo-controlled study L Kappos, G Comi, C Confavreux, MS Freedman, AE Miller, TP Olsson, ... Mult Scler 18 (Suppl 4), 50, 2012 | 38 | 2012 |
| How Does Fingolimod (Gilenya®) Fit in the Treatment Algorithm for Highly Active Relapsing-Remitting Multiple Sclerosis? F Fazekas, O Bajenaru, T Berger, TH Fabjan, AH Ledinek, G Jakab, ... Frontiers in neurology 4, 10, 2013 | 30 | 2013 |
| Identification of a 48 kDa form of unconventional myosin 1c in blood serum of patients with autoimmune diseases S Myronovkij, N Negrych, T Nehrych, MJ Redowicz, S Souchelnytskyi, ... Biochemistry and biophysics reports 5, 175-179, 2016 | 28 | 2016 |
| Neutrophil-released enzymes can influence composition of circulating immune complexes in multiple sclerosis S Paryzhak, T Dumych, I Mahorivska, M Boichuk, G Bila, S Peshkova, ... Autoimmunity 51 (6), 297-303, 2018 | 27 | 2018 |
| Від вірогідної діагностики до ефективної терапії розсіяного склерозу ТІ Негрич, БВ Сорокін, СК Євтушенко Міжнародний неврологічний журнал 3 (49), 152-158, 2012 | 22 | 2012 |
| Рассеянный склероз: актуальность проблемы в Украине, современные аспекты иммунопатогенеза, клиники, диагностики и лечения. Украинский междисциплинарный консенсус НП Волошина, НН Грицай, ИН Дыкан, СК Евтушенко, ТА Кобысь, ... Новости медицины и фармации, 20-24, 2007 | 21 | 2007 |
| Natalizumab improves ambulation in relapsing− remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM N Voloshyna, E Havrdova, M Hutchinson, T Nehrych, X You, S Belachew, ... European Journal of Neurology 22 (3), 570-577, 2015 | 20 | 2015 |
| Primary results of the SELECTION trial of daclizumab HYP in relapsing multiple sclerosis G Giovannoni, R Gold, K Selmaj, E Havrdova, X Montalban, EW Radue, ... 28th Congress of the European Committee for Treatment and Research in …, 2012 | 18 | 2012 |
| Efficacy and safety results from CARE-MS I: a phase 3 study comparing alemtuzumab and interferon-beta-1a A Coles, V Brinar, DL Arnold, J Cohen, C Confavreaux, EJ Fox Program and abstracts of the 5th Joint Triennial Congress of the European …, 2011 | 17 | 2011 |
Nazar Negrych; Негрич Назар; N. Ne...PhD, Danylo Halytsky Lviv National Medical UniversityПідтверджена електронна адреса в meduniv.lviv.ua
